In plain words

One trial, described in a 2012 review, found that rhodiola lowered CRP, a blood marker of inflammation, five hours after exhausting exercise. A marathon trial and a smaller four-week study found no difference from placebo in inflammation markers.

The short answer

Two of the three studies that measured inflammation found no difference from placebo. Shanely and colleagues (2013) gave 48 people rhodiola or placebo for 30 days before a marathon; CRP and cytokines rose in both groups alike. Parisi and colleagues (2010) followed 14 people for 4 weeks and found inflammatory markers unaffected; the ledger has no dose for either study. The third, a trial described in Ishaque and colleagues' 2012 systematic review, found lower CRP 5 hours after exhausting exercise; the ledger has no n, dose or duration for it. Certainty is very low: the studies are few and small, and the one positive result reaches us second-hand.

The 60-second version

Every study in the video is listed below, with its quote.

Watch on YouTube

Where the evidence sits

CRP lower with rhodiola

■ Randomized trial, Ishaque et al., 2012 · ledger has no n

No difference from placebo

■ Randomized trial, Shanely et al., 2013 · 48 people · 30 days
■ Cohort study, Parisi et al., 2010 · 14 people · 4 weeks

■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data

Evidence weight3636 / 100?

Who says what

SourceFindingDesignPeopleDose and lengthFunding and independence
Shanely et al., 2013CRP and cytokines rose after the marathon, no difference from placeboRandomized trial with placebo group48Not in ledger; 30 daysNot in ledger
Parisi et al., 2010Inflammatory markers unaffectedSmall study compared with placebo14Not in ledger; 4 weeksNot in ledger
Ishaque et al., 2012CRP lower at 5 hours; creatine kinase not lowerSystematic review describing an included randomized trialNot in ledgerNot in ledgerNot in ledger
Skarpanska-Stejnborn et al., 2009Related outcome: antioxidant capacity higher, oxidative damage unchangedRandomized, double-blinded trial22 rowers100 mg twice a day for 4 weeksNot in ledger
Shanely et al., 2013

CRP and cytokines rose after the marathon, no difference from placebo

Design
Randomized trial with placebo group
People
48
Dose and length
Not in ledger; 30 days
Funding
Not in ledger
Parisi et al., 2010

Inflammatory markers unaffected

Design
Small study compared with placebo
People
14
Dose and length
Not in ledger; 4 weeks
Funding
Not in ledger
Ishaque et al., 2012

CRP lower at 5 hours; creatine kinase not lower

Design
Systematic review describing an included randomized trial
People
Not in ledger
Dose and length
Not in ledger
Funding
Not in ledger
Skarpanska-Stejnborn et al., 2009

Related outcome: antioxidant capacity higher, oxidative damage unchanged

Design
Randomized, double-blinded trial
People
22 rowers
Dose and length
100 mg twice a day for 4 weeks
Funding
Not in ledger

What happened to CRP after a marathon?

Shanely and colleagues (2013) randomized 48 people to rhodiola or placebo for 30 days, then measured blood markers around a marathon. The ledger has no dose for this trial. Inflammation rose in everyone:

C-reactive protein (CRP), and eHSP72 all increased post-marathon (all p<0.001), with no group differences over time (all p>0.300)

Which trial found lower CRP?

Ishaque and colleagues' 2012 systematic review of rhodiola for fatigue describes one included trial that took blood after an exhausting exercise test. The review reports that CRP was lower with rhodiola, while creatine kinase, a marker of muscle damage, was not:

Findings indicate that R. rosea significantly lowered CRP levels at 5 hours

The ledger holds this result only as the review reports it, with no n, dose or duration.

Did a smaller study see any change?

Parisi and colleagues (2010) compared rhodiola with placebo in 14 people over 4 weeks, measuring antioxidant and inflammation markers in blood. The ledger has no dose for this study:

Blood antioxidant status and inflammatory parameters resulted unaffected by Rhodiola Rosea supplementation.

What about the closely related oxidative stress markers?

Skarpanska-Stejnborn and colleagues (2009) gave 22 professional rowers 100 mg twice a day or placebo for 4 weeks. Total plasma antioxidant capacity ended higher in the rhodiola group (p = .0002), but the authors drew a limit:

supplementation with R. rosea increased antioxidant levels in the plasma of professional rowers but had no effect on oxidative damage induced by exhaustive exercise

The ledger has no inflammation markers for this trial, so it sits outside the count above.

Why the sources disagree

The positive CRP result comes through a review describing someone else's trial, while the two null results come from the researchers' own studies. The exercise differed: a laboratory exhaustion test in the reviewed trial, a full marathon in Shanely's. Blood was drawn at 5 hours in the reviewed trial; the ledger has no sampling times for Shanely's trial beyond "over time". Training status may differ between groups. The ledger has no dose for any of the three inflammation studies, and funding is not in the ledger for any of the four sources.

What would settle it

A placebo-controlled trial giving 600 mg a day for 30 days, with CRP and cytokines measured before, 5 hours after and 24 hours after the same exhausting laboratory test, in at least 100 trained adults, with CRP at 5 hours pre-registered as the main outcome. A matching result from a second research group would raise certainty.

How this page was made

The 4 sources are the studies in the Longevity Circle ledger that measured inflammation or closely related blood markers after rhodiola, drawn from a literature search of rhodiola trials and reviews on PubMed. Safety studies and studies on mood, fatigue and cognition were left out because they did not measure inflammation. Every claim was copied word for word from its source into the ledger and checked against the original text, and a person approved each one. "Contested" means independent studies point in both directions; certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.

The ledger holds only 2 studies on this question.

Changelog: 23 Sep 2026, first version, 4 sources.